Repligen RG3039 Now in Phase 1b Trial dne October 06, 2012 Quinazoline Repligen RG3039 spinal muscular atrophy cure spinal muscular atrophy research +
Repligen reports no adverse effects in phase 1 clinical study so far dne October 30, 2011 Quinazoline Repligen RG3039 spinal muscular atrophy cure spinal muscular atrophy research +
The Current Status of Spinal Muscular Atrophy Therapeutics dne October 16, 2011 ISIS SMNrx Olesoxime Quinazoline spinal muscular atrophy spinal muscular atrophy cure spinal muscular atrophy research stem cell Trophos +